General Discussions

Disparities Exist in Delivering Innovative Cancer Therapies

By John Sweetenham, MD, FACP, FRCP
PUBLISHED WEDNESDAY, DECEMBER 31, 1969


Delivering new and innovative cancer therapies, such as CAR T-cell therapy, come with disparities, explained John Sweetenham, MD, FACP, FRCP, director of clinical affairs and physician in chief at Huntsman Cancer Institute, University of Utah, in Salt Lake City.

These disparities go beyond those that first come to mind, such as race and ethnicity. Patients face barriers in entering clinical trials and receiving the latest standard of care if they live in rural areas. 

Three aspects could help fix this problem, said Sweetenham: more education about new advances; more robust funding systems; and a more sophisticated technological platform for clinicians to communicate with patients.

 
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.